Theriva Biologics Advances VCN-01 with FDA Guidance

Theriva Biologics ( (TOVX) ) just unveiled an update.

Theriva Biologics announced key FDA guidance for a Phase 3 study of its cancer treatment VCN-01, following successful enrollment in a Phase 2b study. The FDA endorsed a stand-alone Phase 3 study design without additional chemotherapy, streamlining the path for advancing this promising therapy for metastatic pancreatic cancer. This decision aligns with Theriva’s strategy to offer new treatment options in areas of high unmet need.

Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.